Novo Holdings

Supira Medical, Inc. is a medical device company that specializes in developing a percutaneous ventricular assist device (pVAD) aimed at high-risk patients undergoing interventional procedures. This innovative device provides temporary mechanical support to assist the heart's native pumping action, making it a critical solution for patients facing severe coronary artery disease or cardiogenic shock during coronary interventions. The company's technology is designed to facilitate recovery in patients who require urgent mechanical support, thereby enhancing their ability to undergo necessary medical procedures. Founded in 2012 and based in Campbell, California, Supira Medical was previously known as Lumenblation Medical, Inc. before rebranding in March 2016.

Biocomposites Limited is a manufacturer and distributor of calcium compound devices designed for surgical applications focused on bone and soft tissue regeneration and repair. The company's product portfolio includes STIMULAN, a pharmaceutical-grade calcium sulfate that aids in infection management and enhances surgical outcomes; geneX, an absorbable synthetic bone graft material that promotes accelerated bone growth; and Allogran-R, a porous calcium phosphate substitute providing an osteoconductive scaffold for trauma and spine applications. Additionally, Biocomposites offers Bilok, an arthroscopic device for ligament reconstruction, and Biosteon, a technology aimed at improving implant and bone integration through interference screws. The products serve various medical needs, including musculoskeletal infections, trauma, spine surgery, and sports injuries. Established in 1996 and headquartered in Keele, United Kingdom, Biocomposites is dedicated to advancing treatment options in orthopedic care.

FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Magenta Medical Ltd. is a privately held company based in Kadima, Israel, founded in 2012. The company specializes in developing innovative medical devices aimed at treating acute decompensated heart failure. Its flagship product is a temporary venous catheter-based therapy that includes a self-expanding heart pump. This device targets critical issues related to acute heart failure, particularly renal venous congestion, which adversely affects both cardiac and renal function. By enabling physicians to more effectively manage fluid and salt removal in patients, Magenta Medical's technology enhances patient safety and supports kidney function, offering a promising solution for better management of heart failure.

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases. Tauopathies are currently untreatable neurodegenerative diseases that rapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.

Cargo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation CAR T-cell therapies aimed at overcoming cancer treatment resistance and improving patient access to potentially curative options. The company aims to enhance treatment outcomes by addressing the limitations of existing therapies, which currently provide curative benefits to less than half of cancer patients. Its lead program, CRG-022, is a novel CAR T-cell product candidate that targets CD22, a tumor antigen prevalent in many B-cell malignancies. By tackling issues such as limited durability, safety concerns, and supply chain obstacles, Cargo Therapeutics is committed to advancing innovative solutions that make effective cancer treatments more accessible to patients.

LEXEO Therapeutics is a biotechnology company that specializes in the development of gene therapies, particularly those utilizing adeno-associated virus (AAV) technology. The company’s pipeline includes both rare and non-rare monogenic diseases, with a strong emphasis on hereditary and acquired conditions that present significant unmet medical needs. LEXEO's lead programs and preclinical candidates are primarily developed in collaboration with Weill Cornell Medicine’s Department of Genetic Medicine. The company aims to advance its clinical programs toward commercialization while maintaining an ongoing research partnership with Weill Cornell to enhance its preclinical efforts. Through its innovative approach, LEXEO Therapeutics seeks to transform the treatment landscape for diseases that impose a substantial burden on patients and society.

FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.

Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.

Inbrace is a medical device company focused on innovative orthodontic solutions. Its flagship product, INBRACE, is a discreet alignment system that is placed behind the teeth, utilizing patented self-guiding technology to apply continuous forces for gentle correction of dental alignment. This approach significantly reduces pain and minimizes the number of required visits to the orthodontist, addressing common patient concerns and enhancing satisfaction. INBRACE is FDA registered and aims to expand access to orthodontic treatment, thereby driving practice growth for dental professionals. The company's platform incorporates digital treatment planning, computer modeling, and direct digital manufacturing, allowing for customized solutions that maintain high standards of care across various orthodontic cases.

Availity, L.L.C. is a healthcare technology company based in Jacksonville, Florida, that specializes in Internet-based health information exchange services. Founded in 2001, Availity focuses on optimizing the flow of information between healthcare providers, health plans, and various stakeholders through its comprehensive platform. The company offers a range of services, including CareRead, which automates patient information entry using member ID cards, and CareProfile, which provides access to electronic health records. Additionally, Availity supports patient communication through online interaction, appointment scheduling, and referral requests. Its CarePrescribe solution facilitates electronic prescribing by offering real-time access to medication histories and drug interaction checks. The CareCost Estimator tool enables healthcare providers to determine a patient's financial responsibility at the point of care, while CareCollect streamlines the collection of patient payments. Availity serves a diverse array of healthcare providers, such as physician offices, hospitals, and pharmacies, enhancing administrative efficiency and transparency in the healthcare industry.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Tempus is a technology company improving precision medicine through the practical application of artificial intelligence in healthcare. Their platform is designed to analyze and interpret clinical and molecular data to help healthcare providers deliver more personalized and effective treatments.

Tempus is a technology company improving precision medicine through the practical application of artificial intelligence in healthcare. Their platform is designed to analyze and interpret clinical and molecular data to help healthcare providers deliver more personalized and effective treatments.

Mission Bio, Inc. is a biotechnology company that specializes in tools for studying cellular heterogeneity in human health and life sciences. The company has developed the Tapestri Platform, the first single-cell multi-omics platform, which allows for the simultaneous analysis of genotype and phenotype from the same cell. This platform utilizes proprietary microfluidic droplet technology to enable precise detection of genomic variability at single-cell resolution, facilitating research in various applications, including oncology, blood cancers, solid tumors, and genome editing. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating customized single-cell DNA panels, further enhancing its capabilities in targeted molecular analysis. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.

Reapplix ApS, founded in 2008 and based in Birkerod, Denmark, is a research and development company focused on improving wound healing through the use of blood-derived proteins. The company identifies and isolates these proteins to create a tissue regeneration device that provides biological treatment for chronic wounds, particularly diabetic foot ulcers. By utilizing a platform that delivers evidence-based biological wound therapy made entirely from a patient's own blood, Reapplix enables hospitals to offer autologous active cell therapy. This approach allows patients to leverage their own biological materials for enhanced healing outcomes.

Tempus is a technology company improving precision medicine through the practical application of artificial intelligence in healthcare. Their platform is designed to analyze and interpret clinical and molecular data to help healthcare providers deliver more personalized and effective treatments.

Clario delivers the endpoint technology solutions for clinical trials. Clario fuses scientific expertise and global scale into the broadest endpoint technology platform to enable pharmaceutical, biotech and medical device partners to transform lives. Through Trial Anywhere™, Clario has mastered the ability to generate rich evidence across all trial models: decentralized, hybrid and site-based clinical trials. With 30 facilities in nine countries across North America, Europe and Asia Pacific, Clario's global team of science, technology and operational experts has been delivering the richest clinical evidence for nearly 50 years.

Inbrace is a medical device company focused on innovative orthodontic solutions. Its flagship product, INBRACE, is a discreet alignment system that is placed behind the teeth, utilizing patented self-guiding technology to apply continuous forces for gentle correction of dental alignment. This approach significantly reduces pain and minimizes the number of required visits to the orthodontist, addressing common patient concerns and enhancing satisfaction. INBRACE is FDA registered and aims to expand access to orthodontic treatment, thereby driving practice growth for dental professionals. The company's platform incorporates digital treatment planning, computer modeling, and direct digital manufacturing, allowing for customized solutions that maintain high standards of care across various orthodontic cases.

Tempus is a technology company improving precision medicine through the practical application of artificial intelligence in healthcare. Their platform is designed to analyze and interpret clinical and molecular data to help healthcare providers deliver more personalized and effective treatments.

Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.

ConvaTec Inc. is a global medical technology company based in Bridgewater, New Jersey, that specializes in manufacturing and marketing medical products and services for the management of chronic conditions. Founded in 1978, the company offers a range of therapies, including advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products are designed to improve the quality of life for patients and support caregivers in managing various health challenges effectively. As a subsidiary of Convatec Group Plc, ConvaTec continues to focus on innovation and excellence in its medical offerings.

AMRA is an international medical technology company specializing in precision medicine through advanced imaging techniques. It is the first organization to convert MRI images into precise body composition measurements using a cloud-based service. AMRA collaborates with leading pharmaceutical companies, research institutions, hospitals, and biobanks to enhance metabolic research and therapeutic applications. Their technology generates detailed biomarkers related to fat and muscle composition, providing medical professionals with insights into genetics, lifestyle, and biological factors. This capability enables healthcare providers to monitor clinically significant changes in body composition, ultimately aiding in the prediction and prevention of diseases.

Minerva Surgical Inc. is a medical technology company based in Redwood City, California, specializing in women's healthcare. Founded in 2008, the company develops, manufactures, and commercializes minimally invasive solutions aimed at addressing the unique uterine health needs of women. Its flagship product, The Minerva Endometrial Ablation System, provides a treatment option for abnormal uterine bleeding, a common issue among women. Minerva Surgical offers a range of alternatives to hysterectomy, designed to tackle the leading causes of abnormal uterine bleeding while preserving the uterus and minimizing the drawbacks associated with traditional treatment methods. The company's solutions are suitable for various medical settings, reflecting its commitment to improving women's health outcomes.

CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.

Reapplix ApS, founded in 2008 and based in Birkerod, Denmark, is a research and development company focused on improving wound healing through the use of blood-derived proteins. The company identifies and isolates these proteins to create a tissue regeneration device that provides biological treatment for chronic wounds, particularly diabetic foot ulcers. By utilizing a platform that delivers evidence-based biological wound therapy made entirely from a patient's own blood, Reapplix enables hospitals to offer autologous active cell therapy. This approach allows patients to leverage their own biological materials for enhanced healing outcomes.

Clario delivers the endpoint technology solutions for clinical trials. Clario fuses scientific expertise and global scale into the broadest endpoint technology platform to enable pharmaceutical, biotech and medical device partners to transform lives. Through Trial Anywhere™, Clario has mastered the ability to generate rich evidence across all trial models: decentralized, hybrid and site-based clinical trials. With 30 facilities in nine countries across North America, Europe and Asia Pacific, Clario's global team of science, technology and operational experts has been delivering the richest clinical evidence for nearly 50 years.

Spectranetics is a medical technology company based in Colorado that specializes in developing single-use tools for minimally invasive cardiovascular surgeries. The company focuses on lead management, as well as peripheral and coronary interventions, offering advanced products such as scoring balloon technology and laser atherectomy. Spectranetics provides healthcare providers with innovative solutions and proven algorithms to effectively manage cardiac leads, modify plaque, and address complications like restenosis and amputation. With a commitment to product innovation, Spectranetics continually explores new methods to enhance the effectiveness and efficiency of complex cardiovascular procedures, ultimately aiming to improve patient outcomes and quality of life.

Cardeas Pharma is focused on developing a novel antibiotic formulation that combines two drugs to effectively target highly resistant Gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, as well as carbapenem-resistant Enterobacteriaceae. This formulation is also effective against biofilms and Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). The antibiotics are delivered through a single-patient use nebulizer that produces small, uniform aerosol droplets, allowing for targeted delivery to the small airways and alveoli. By integrating this innovative antibiotic formulation with advanced drug-delivery technology, Cardeas Pharma aims to improve clinical outcomes for patients suffering from serious, hospital-acquired respiratory infections.

iRhythm Technologies is a digital healthcare company that specializes in ambulatory electrocardiogram (ECG) monitoring for patients at risk of arrhythmias in the United States. Its flagship product, the Zio service, features a wire-free, patch-based biosensor designed for comfortable wear, enabling continuous monitoring of heart activity for up to 14 days. This wearable technology is complemented by a cloud-based data analytics platform that utilizes machine learning to transform extensive heartbeat data into actionable clinical insights. iRhythm aims to enhance the early diagnosis and treatment of cardiac arrhythmias, ultimately improving patient health outcomes while reducing unnecessary healthcare costs. Established in 2006 and headquartered in San Francisco, the company also collaborates with Verily Life Sciences to develop advanced atrial fibrillation monitoring solutions.

Ceterix Orthopaedics, Inc. is a medical technology company focused on developing innovative surgical tools for arthroscopic procedures. Based in Fremont, California, the company offers the Ceterix NovoStitch® Plus Meniscal Repair System, designed to repair various complex meniscal tears, including horizontal, radial, and root tears. Additionally, Ceterix provides the Novocut Suture Manager, a device that facilitates suture management during surgeries. The company's technology allows orthopedic surgeons to non-invasively create intricate suture patterns in tight joint compartments while safeguarding surrounding structures such as nerves and cartilage. Founded in 2010 by Dr. Justin Saliman, an orthopedic surgeon specializing in sports medicine, Ceterix aims to enhance the outcomes of arthroscopic procedures, addressing issues that often lead to untreated tears or the more invasive meniscectomy. As of January 2019, Ceterix operates as a subsidiary of Smith & Nephew plc.

Nevro is a global medical device company dedicated to enhancing the quality of life for patients suffering from chronic pain. The company's primary product is the HFX spinal cord stimulation (SCS) platform, which features the Senza SCS system. This innovative neuromodulation system delivers Nevro's proprietary HF10 therapy, designed to provide effective pain relief through electrical impulses. The Senza system, which is implanted by physicians, includes essential components such as leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. Nevro primarily generates its revenue from the United States market, focusing on evidence-based solutions for chronic pain management.

Flexion Therapeutics, Inc. is a biopharmaceutical company based in Burlington, Massachusetts, dedicated to the discovery, development, and commercialization of therapies for musculoskeletal conditions, particularly osteoarthritis. The company offers ZILRETTA, an intra-articular injection designed to manage knee pain associated with osteoarthritis in the United States. Additionally, Flexion is developing FX201, a gene therapy aimed at stimulating the production of an anti-inflammatory protein to provide pain relief, and FX301, a NaV1.7 inhibitor intended for post-operative pain management. Founded in 2007, Flexion Therapeutics collaborates with pharmaceutical and biotechnology companies to advance its drug candidates through clinical proof of concept and beyond, thereby enhancing their partners' portfolios while sharing expertise and risk.

Cardeas Pharma is focused on developing a novel antibiotic formulation that combines two drugs to effectively target highly resistant Gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, as well as carbapenem-resistant Enterobacteriaceae. This formulation is also effective against biofilms and Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). The antibiotics are delivered through a single-patient use nebulizer that produces small, uniform aerosol droplets, allowing for targeted delivery to the small airways and alveoli. By integrating this innovative antibiotic formulation with advanced drug-delivery technology, Cardeas Pharma aims to improve clinical outcomes for patients suffering from serious, hospital-acquired respiratory infections.

Inogen is a medical technology company that specializes in the development and manufacturing of portable oxygen concentrators for patients with chronic respiratory conditions. Its flagship product, the Inogen One system, offers a lightweight and convenient alternative to traditional stationary oxygen concentrators and oxygen tanks. Inogen markets its products to home medical equipment providers and directly rents them to patients. The company also operates internationally, distributing its products through large gas companies and home oxygen providers. While it serves a global market, the majority of its revenue is generated in the United States. Inogen is committed to enhancing the freedom and independence of oxygen therapy patients through innovative products and superior service.

Apollo Endosurgery, Inc. is a medical technology company based in Austin, Texas, that specializes in the design, development, and commercialization of devices for gastrointestinal therapeutic endoscopy. Founded in 2005, the company offers a range of innovative products aimed at reducing the need for invasive surgical procedures. Key offerings include the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which allow physicians to place full-thickness sutures through a flexible endoscope, and the X-Tack Endoscopic HeliX Tacking System. Additionally, Apollo provides the Orbera Intragastric Balloon, which helps manage obesity by reducing stomach capacity. The company's solutions are designed to lower complication rates and overall healthcare costs, making them valuable tools for gastroenterologists and bariatric surgeons. Apollo Endosurgery distributes its products to medical service providers, hospitals, outpatient surgical centers, clinics, and physicians across the United States, Brazil, Australia, and various European countries.

Celltrix is a Swedish biotechnology/medical device company focusing on reconstructive cosmetic surgery. Research, development and production are based in Malmö. They plan to launch the first product –Credurance – in 2010. Their product represents a new type of dermal filler. An immediate filling effect is achieved and the surrounding cells are presented to a matrix suitable for cell growth. As the cells grow on and inside the matrix, they produce their own environment, natural collagen, which gradually replaces the matrix — biorestoring.

Protein Forest, Inc. specializes in the development, manufacturing, and marketing of instruments, consumables, and software products aimed at protein separation and bioanalysis applications. Based in Lexington, Massachusetts, the company provides innovative solutions such as the digital ProteomeChip (dPC), which fractionates and concentrates proteins or peptides through isoelectric focusing, facilitating mass spectrometry analysis and western blotting. Its product lineup includes the dPC fractionator, designed to process separate samples under controlled conditions, and the dPC PlugHarvestor, which enables users to organize pH gel plugs efficiently. Additionally, Protein Forest offers bioinformatics software that complements its hardware solutions. The company serves a diverse clientele in the life sciences, drug discovery, pharmaceutical, biotech, and diagnostic sectors, contributing to advancements in research and development since its founding in 2002.

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.